Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Arbor Pharmaceuticals LLC is allegedly exploring a potential acquisition and merger partner that could bring in more than $1 billion, according to people who are close to the situation.

Pfizer Inc. has approached Actavis with a possibility to acquire the company.

Akorn targets UCB’s subsidiary for acquisition for tax inversion. 

Belgium-based healthcare company Omega Pharma NV is allegedly attracting numerous bids from businesses across the big pharma companies, according to Bloomberg Businessweek. Perrigo and Boehringer Ingelheim GmbH are rumored to be interested in acquiring the company. 

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs.